Abstract
Objective To compare the efficiencies of imatinib and dasatinib in patients with chronic myeloid leukemia-chronic phase (CML-CP). Methods The databases were retrieved, including Cochrane Library, OVID, Embase, PubMed, China National Knowledge Infrastructure (CNKI), WanFang database and VIP database, besides, references of articles were further to search. The quality of randomized controlled trials (RCTs) was assessed by the Cochrane collaboration's risk tool. Meta-analysis was performed by RevMan 5.1 software. Results A total of 5 articles involved 2 031 patients with CML-CP were included. Meta-analysis showed that the rate of complete cytogenetic response (CCyR) at the 12th month in dasatinib group was higher than that in imatinib group [83.6 % (478/572) vs 70.6 % (406/575), OR = 2.11, 95 % CI 1.59-2.80, P < 0.05], and the rate of major molecular response (MMR) at the 12th month in dasatinib group was higher than that in imatinib group [49.3 % (296/600) vs 30.6 % (185/605), OR = 2.22, 95 % CI 1.75-2.82, P < 0.05]. Conclusion Dasatinib can improve CCyR and MMR rate at the 12th month in CML-CP patients. Key words: Leukemia, myeloid, chronic; Dasatinib; Imatinib; Meta-analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
